HNN3.0

Project cooperationUpdated on 23 January 2026

Advancing Horizon Europe projects through microbiota and metabolomics for translational and clinical research

Full Professor Clinical Pathology and Head of Laboratory Unit at Fondazione Policlinico Universitario Campus Bio-Medico

Rome, Italy

About

Prof. Silvia Angeletti is a Full Professor of Clinical Microbiology at Università Campus Bio-Medico di Roma, with consolidated expertise in microbiota research, metabolomics and host–microbe interactions in both clinical and translational settings.

Her research focuses on understanding how microbial communities and their metabolic outputs influence human health and disease, integrating microbiological, metabolomic and clinical data to identify biomarkers, therapeutic targets and predictive signatures relevant to patient stratification and personalized medicine.

Key areas of expertise include:

  • Human microbiota profiling in health and disease

  • Metabolomics approaches for the study of microbe-derived and host metabolites

  • Host–microbiota interactions in inflammatory, infectious and systemic diseases

  • Integration of multi-omics data (microbiota, metabolomics, clinical parameters)

  • Identification and validation of biomarkers for diagnosis, prognosis and treatment response

Prof. Angeletti has strong experience in multidisciplinary and international research projects, working at the interface between basic science, clinical research and systems biology. Her contribution to Horizon Europe consortia is particularly valuable for projects requiring a translational and clinically relevant interpretation of microbiota and metabolomics data.

She is interested in participating in Horizon Europe collaborative projects as a partner contributing:

  • Expertise in study design and interpretation of microbiota and metabolomics data

  • Access to well-characterized clinical cohorts and biological samples

  • Support in multi-omics integration and biomarker discovery

  • Clinical validation and translational exploitation of project results

She is particularly open to collaborations addressing:

  • Microbiota-driven mechanisms of disease

  • Microbiome-based diagnostics and therapeutic strategies

  • Diet, metabolism and host–microbe crosstalk

  • Personalized and precision medicine approaches

  • One Health and systems biology frameworks

The Campus Bio-Medico of Rome provides a highly integrated clinical and translational research environment, enabling the effective exploitation of microbiota and metabolomics research within Horizon Europe projects and enhancing their scientific and societal impact.

Topic

  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

Organisation

Similar opportunities

  • Project cooperation

    Clinical microbiology and advanced diagnostics for infectious diseases and antimicrobial resistance in Horizon Europe projects

    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

    Silvia Angeletti

    Full Professor Clinical Pathology and Head of Laboratory Unit at Fondazione Policlinico Universitario Campus Bio-Medico

    Rome, Italy

  • Project cooperation

    Health projects at Eurecat

    • Consortium/Coordinator seeks Partners
    • Partner seeks Consortium/Coordinator
    • DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-04: Towards climate resilient, prepared and carbon neutral populations and healthcare systems
    • DESTINATION 2: HORIZON-HLTH-2026-01-ENVHLTH-01: Towards a better understanding and anticipation of the impacts of climate change on health
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-02: Innovative interventions to prevent the harmful effects of using digital technologies on the mental health of children and young adults

    MARTA SANS VALLS

    European Programme Manager at Fundacio Eurecat

    Barcelona, Spain

  • Project cooperation

    Mass Spetrometry Metabolomics: Bioactive Metabolites and Host-Microbiota Interactions

    • Partner seeks Consortium/Coordinator
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)

    Zdenek Kamenik

    Research group leader at Institute of Microbiology Czech Acad Sci

    Praha, Czech Republic